IO Biotech (NASDAQ:IOBT – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07), Zacks reports.
IO Biotech Stock Performance
IOBT stock traded up $0.04 during trading on Wednesday, hitting $0.97. The company had a trading volume of 293,909 shares, compared to its average volume of 228,295. IO Biotech has a one year low of $0.73 and a one year high of $2.10. The business has a 50-day moving average of $1.09 and a 200-day moving average of $1.26.
Analyst Ratings Changes
Several research analysts have recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and issued a $10.00 price objective on shares of IO Biotech in a report on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of IO Biotech in a report on Tuesday. Finally, Morgan Stanley boosted their price objective on shares of IO Biotech from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Monday, September 16th.
About IO Biotech
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Featured Articles
- Five stocks we like better than IO Biotech
- Are Penny Stocks a Good Fit for Your Portfolio?
- Rocket Lab is the Right Stock for the Right Time
- Investing In Preferred Stock vs. Common Stock
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Quiet Period Expirations Explained
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.